HOME   
   NEWS   
   BUSINESS   
   CRICKET   
   SPORTS   
   MOVIES   
   NET GUIDE   
   SHOPPING   
   BLOGS  
   ASTROLOGY  
   MATCHMAKER  


Search:



The Web

Rediff








Business
Portfolio Tracker
Business News
Specials
Columns
Market Report
Mutual Funds
Interviews
Tutorials
Message Board
Stock Talk



Home > Business > Corporate Headline > Quick Company Info

Risc

Morepen expects sales to rise by Rs 100 cr

February 11, 2003 14:28 IST

Morepen Laboratories expects revenues and net to rise by $20 million (Rs 1000 million) and $10-12 million (Rs 500-600 million) respectively, enhanced by a 180-day marketing exclusivity granted to Geneva Pharmaceuticals Inc for Loratadine in the U S.

Morepen is the sole supplier for bulk Loratadine to Geneva Pharma, an arm of Novartis AG. Geneva Pharma already launched its generic version of Claritin in the US market.

BSE Code: 500288



Article Tools

Email this Article

Printer-Friendly Format

Letter to the Editor



Related Stories


Caraco gets FDA OK for cardiac drug

Ranbaxy slips on institutional sale

Ranbaxy launches Augmentin clone



People Who Read This Also Read


Aftek Info allots shares

Banks plan to raise lending rates

Tata Chem, Indo-Gulf eye Nat Fert







HOME   
   NEWS   
   BUSINESS   
   CRICKET   
   SPORTS   
   MOVIES   
   NET GUIDE   
   SHOPPING   
   BLOGS  
   ASTROLOGY  
   MATCHMAKER  
© 2003 rediff.com India Limited. All Rights Reserved.